Big pharma against CL move but WHO agrees


Right to get treatment: It was reported last year that there were 400,000 Hepatitis C sufferers in Malaysia, with only a fraction who could afford the RM300,000 cost. — AFP

KUALA LUMPUR: Malaysia’s bold move to impose compulsory licence (CL) on the drug sofosbuvir has been heavily criticised by big pharmaceutical companies, but has the support of the World Health Organisation (WHO).

WHO advocates universal health coverage and that means access to life-saving treatment, said its head of mission and representative to Malaysia, Brunei and Singapore Dr Lo Ying-Ru.

The Star Christmas Special Promo: Save 35% OFF Yearly. T&C applies.

Monthly Plan

RM 13.90/month

Best Value

Annual Plan

RM 12.33/month

RM 8.02/month

Billed as RM 96.20 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Nation

Our ally has gone its own way, PAS Youth chief says in heartfelt post
One dead, one hurt after motorcycles hit cow on AMJ Highway
Man charged with causing the deaths of three others by dangerous driving
After Perlis MB issue, PAS division youth wing wants party to cut ties with Bersatu
Floods: One more relief centre opens in Segamat
‘Cowboy town’ comes alive during school holidays
Prices of mandarins to stay stable
Couple forever united in afterlife
166kg of waste collected at Marang beach
Pawsitive Initiative ends year on a high note

Others Also Read